NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development of novel therapies for central nervous system ailments and life-threatening lung conditions. Its portfolio includes ZYESAMI, an investigational medicine that has progressed through Phase IIb/III clinical trials for severe respiratory distress linked to COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, orally administered treatments engineered to address bipolar depression in individuals exhibiting both acute and sub-acute suicidal ideation and actions. This Delaware-based company, located in Wilmington, was established in 2015.